Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AGLE

AGLE - Aeglea BioTherapeutics Inc Stock Price, Fair Value and News

$27.60-0.08 (-0.29%)
Delayed as of 30 Jan 2024, 04:00 pm ET

Price Targets

AGLE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AGLE Price Action

AGLE RSI Chart

AGLE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AGLE Valuation

Market Cap

2.2B

Price/Earnings (Trailing)

-12.08

Price/Sales (Trailing)

87.63

EV/EBITDA

-11.54

Price/Free Cashflow

-11.68

AGLE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

AGLE Fundamentals

AGLE Revenue

Revenue (TTM)

24.7M

Rev. Growth (Yr)

7.73%

Rev. Growth (Qtr)

30.04%

AGLE Earnings

Earnings (TTM)

-179.4M

Earnings Growth (Yr)

-54.12%

Earnings Growth (Qtr)

-10.36%

AGLE Profitability

EBT Margin

-725.25%

Return on Equity

-26.75%

Return on Assets

-23.49%

Free Cashflow Yield

-8.56%

AGLE Investor Care

Shares Dilution (1Y)

30.80%

Diluted EPS (TTM)

-1.98

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202624.7M000
202522.0M23.5M22.9M0
20245.1M10.4M15.5M0
20231.2M1.2M1.1M886.0K
202220.1M7.0M5.8M2.3M
20215.5M9.9M14.3M18.7M
20202.0M1.7M1.1M0
20192.9M1.1M1.7M0
20185.7M6.6M5.4M3.9M
20175.6M7.0M8.2M5.2M
201647.0K116.0K183.0K4.6M
20156.3K11.5K16.8K22.0K
20140001.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Aeglea BioTherapeutics Inc

AGLE
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
 WEBSITEaeglea.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES14

Aeglea BioTherapeutics Inc Frequently Asked Questions

AGLE is the stock ticker symbol of Aeglea BioTherapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Mar 31 2026, market cap of Aeglea BioTherapeutics Inc is 2.17 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Tue Mar 31 2026, AGLE's PE ratio (Price to Earnings) is -12.08 and Price to Sales (PS) ratio is 87.63. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AGLE PE ratio will change depending on the future growth rate expectations of investors.